India's Sun To Sue Novartis To Allow Generic Before Patent Expiration
This article was originally published in PharmAsia News
Executive Summary
Sun Pharma reportedly has reversed the usual legal practice and sued Novartis in a U.S. court, seeking authority to market a generic version of the Glivec (imatinib) (marketed as Gleevec in the U.S.) cancer drug before the Swiss-based drug maker's patent expires.